ISM6200

ISM6200 is a preclinical **small-molecule selective NR3C1 inhibitor/antagonist** being developed by Insilico Medicine for cortisol-excess-related disorders and oncology indications, including ovarian cancer, Cushing's syndrome, hypercortisolism-associated obesity, and glaucoma. NR3C1 encodes the glucocorticoid receptor, a nuclear hormone receptor that mediates cortisol signaling across stress-response, metabolic, immune, and inflammatory pathways. According to public company disclosures, ISM6200 was designed using Insilico's Pharma.AI and Chemistry42 platforms and has been described as a potentially best-in-class program with favorable ADME/PK properties, low predicted drug-drug interaction risk, low predicted efficacious human dose, and dose-dependent anti-tumor activity in combination with paclitaxel in preclinical xenograft models.